The value of engaging non‑traditional and emerging sites is widely recognized, yet many of these sites continue to be overlooked due to a lack of prior trial experience. This creates a persistent cycle: sites struggle to build experience without access to studies, while sponsors often prioritize experience when selecting sites—ultimately limiting broader representation in clinical trials.

With funding from Roche | Genentech, Duke Clinical Research Institute, and National Medical Fellowships, and support from Continuum Clinical, ACRP and its collaborators will share preliminary findings from qualitative interviews with sponsors and non‑traditional sites. These insights highlight real‑world barriers to participation in Phase III studies. Attendees will gain practical insight into how rethinking site selection—and more intentionally engaging non‑traditional sites—can support stronger recruitment outcomes while advancing meaningful representation.

CEU: 1.00 ACRP

Speakers:

• Ruma Bhagat, MD, MPH, Senior Director, Health Equity & Population Science, Genentech

• Pete Fronte, MBA, President & CEO, Altura

• Karen Lipworth, Communications Strategist and Senior Medical Writer, ACRP